• GSK J4 HCl: From Chromatin to Translation

  2026-08-20

  GSK J4 HCl offers translational researchers a cell-permeable way to interrogate JMJD3-dependent H3K27 demethylation across inflammation, decidual immune regulation, and K27M glioma models. This article connects mechanistic evidence from human decidua with practical study design while distinguishing hypothesis-generating use from clinically validated treatment.

• Arachidonic Acid: From Lipid Flux to Vaccine Response

  2026-08-19

  Explore how Arachidonic Acid connects membrane lipid metabolism with eicosanoid signaling and vaccine-driven humoral immunity. This practical, evidence-grounded guide translates recent findings into better assay design and pathway interpretation.

• Salinomycin Workflows for HCC Research

  2026-08-19

  Build more informative hepatocellular carcinoma assays with Salinomycin by linking viability, apoptosis, calcium flux, ABC transporter activity, and Wnt/β-catenin signaling. This workflow emphasizes concentration control, orthogonal readouts, and ionophore-specific troubleshooting rather than relying on a single cytotoxicity endpoint.

• Primary Antibody Dilution Buffer for PCNSL Assays

  2026-08-18

  Learn how Primary Antibody Dilution Buffer can improve antibody-based detection of metabolic and immune markers relevant to primary CNS lymphoma. This guide connects the K1200 formulation with single-cell findings on SLC2A5, while emphasizing assay controls, tissue penetration, and interpretation limits.

• Position-3 GnRH Antagonists: Degarelix Analog Study

  2026-08-18

  The 2005 reference study examined how replacing degarelix position 3 with racemic 3-(2-methoxy-5-pyridyl)-alanine affected receptor antagonism and in vivo persistence. Its central finding was stereochemistry-dependent activity: the D-configured analog retained nanomolar human GnRH receptor antagonism, whereas the L-configured analog was substantially weaker, and neither analog reproduced degarelix’s long-acting profile.

• Cy3 Goat Anti-Rabbit IgG (H+L) Antibody: Assay Logic

  2026-08-17

  Learn how the Cy3 Goat Anti-Rabbit IgG (H+L) Antibody can convert pathway hypotheses into interpretable imaging evidence in rheumatoid arthritis research. This guide connects the IOP–NF-κB/NLRP3 study with reagent selection, controls, storage, and quantitative assay design.

• Plant Protein Secretion: Methods and Research Insights

  2026-08-17

  The second edition of Plant Protein Secretion: Methods and Protocols advances plant cell biology by organizing conventional and unconventional secretion into reproducible, stepwise experimental workflows. Its key contribution is methodological: it integrates plant-specific endomembrane organization, diverse cell types, troubleshooting guidance, and comparative interpretation to improve experimental design and reproducibility.

• CD38 CAR Binder Structures and Affinity Tuning

  2026-08-16

  The reference study explains how two CD38-targeting CAR binders, RP02 and 028, recognize different antigen surfaces and produce distinct effects on CD38 enzymatic activity. Its structure-guided affinity tuning of 028 reduces CAR-T fratricide while preserving tumor-cell killing, providing a mechanistic framework for balancing potency, selectivity, and safety.

• From ROS Signal to Therapeutic Mechanism: HPF

  2026-08-15

  HPF (hydroxyphenyl fluorescein) gives translational researchers a selective way to connect highly reactive oxygen species detection with mechanistic studies of multimodal phototherapy. This thought-leadership guide explains how to use HPF to distinguish hROS biology from broad oxidative signals, validate phototherapeutic mechanisms, and build more decision-ready cellular evidence.

• DOT1L Inhibition Reprograms Immunity in Myeloma

  2026-08-14

  A 2025 Cancer Letters study shows that DOT1L inhibition suppresses multiple myeloma through both epigenetic growth control and activation of STING-linked innate immune signaling. The work also demonstrates that DOT1L inhibition enhances lenalidomide responses, providing a mechanistic basis for combining epigenetic therapy with immunomodulatory treatment.

• Tetrandrine: From Ion Channels to Assay Design

  2026-08-14

  Tetrandrine is a versatile natural-product alkaloid for ion channel modulation, inflammation, neuroscience, and cancer biology research. This guide presents an evidence-aware framework for connecting its pharmacology with target-based screening and reproducible assay design.

• JNJ-26481585 (Quisinostat) for Resistance Research

  2026-08-13

  JNJ-26481585 (Quisinostat) combines sub-nanomolar HDAC potency with a practical workflow for studying epigenetic control, apoptosis, and treatment resistance. This guide connects histone acetylation and p21 induction with the TRIM21–ERK1/2 axis identified in pituitary adenoma research, while emphasizing assay controls, formulation, and troubleshooting.

• Recombinant Human EGF (P1008) for Reliable Assays

  2026-08-13

  Learn how Epidermal Growth Factor (EGF), human recombinant, SKU P1008 can improve control of proliferation, viability, cytotoxicity, and migration experiments. This scenario-based guide covers product selection, reconstitution, assay compatibility, dose interpretation, and evidence-based workflow safeguards.

• Mianserin HCl: From 5-HT2 Biology to Translation

  2026-08-12

  A translational framework for using Mianserin HCl as a mechanistic serotonergic tool, connecting 5-HT2 receptor pharmacology, placebo-controlled evidence, formulation effects, and emerging antipathogenic research.

• Amyloid Beta-Peptide (1-40) (human): Microglia Workflows

  2026-08-12

  Build reproducible Aβ40 experiments by controlling peptide concentration, aggregation state, storage, and exposure timing. This workflow connects amyloid fibril formation studies with microglial signaling assays inspired by a recent APP-dependent study.

545 records 7/37 page Previous Next First page 上5页 678910 下5页 Last page